Core Viewpoint - The field of automated low-temperature storage for biological samples is experiencing a new surge due to the rapid development of cell therapy and precision medicine, positioning it as a key component of the life sciences "new infrastructure" [2][5]. Company Overview - Shanghai Yuaneng Cell Biology Low-Temperature Equipment Co., Ltd. (Yuaneng Biology) has initiated a Series B financing round with a target of 200 million yuan and plans to go public on the Sci-Tech Innovation Board in two years [2][5]. - The company, founded in 2017, specializes in the research, design, and manufacturing of automated low-temperature storage equipment for biological samples, covering various temperature ranges from -196°C to 8°C [7][10]. Market Potential - The biological sample low-temperature storage sector is still in its early stages, with the market size expected to reach hundreds of billions in the next 5-10 years due to equipment upgrades and new demand [5][12]. - The market share of biological sample banks in the medical low-temperature storage market has exceeded 30% [12]. Technological Innovations - Yuaneng Biology has developed a "hive-style" independent storage structure that eliminates cross-contamination and ensures permanent independent storage of samples, which is crucial for virus sample preservation [8][10]. - The company has introduced a vacuum negative pressure single-tube picking technology that minimizes sample damage and maintains a low activity loss rate of less than 0.3%, outperforming industry averages [10][11]. Product Development and Recognition - Yuaneng Biology's products have received multiple international certifications, including the world's first intelligent deep low-temperature biological sample library and a dual-mode intelligent ultra-low temperature biological sample library [11]. - The Orcella duo™ 1100S automated ultra-low temperature storage system won the "Outstanding New Product Award" from the International Society for Biological and Environmental Repositories (ISBER) in 2025 [11]. Business Strategy - The company is shifting from a "single equipment sales" model to a comprehensive solution covering the entire chain from sample preparation to application [12][14]. - Yuaneng Biology aims to achieve a revenue of 1.3 billion yuan by 2025, with a target of approximately 5 billion yuan by 2027, maintaining an annual growth rate of doubling revenue over the next five years [12][13]. Leadership and Vision - The founder and chairman, Qu Jianguo, emphasizes the importance of proactive health management and the potential for growth in reproductive health, anti-aging, and wellness sectors [14].

Core Insights - Yuaneng Bio is actively preparing for its Series B financing and independent listing after completing a Series A financing of 410 million yuan in 2022 [1] - The company focuses on advanced automated low-temperature storage equipment for biological samples, addressing pain points in the biopharmaceutical industry [1] Group 1 - Yuaneng Bio was founded by Qu Jianguo, who has a history of successful entrepreneurial ventures, including transforming Shenhua Industry and founding Kaineng Health [1] - The company has developed a comprehensive product system that offers innovative solutions for various temperature ranges, sample types, and storage scales, including features like liquid nitrogen cold chain protection and remote management via 5G IoT [1] - As of December 2024, Yuaneng Bio has applied for over 600 domestic and international patents, with more than 500 granted [1] Group 2 - Yuaneng Bio's overseas brand, Orcella Instruments, won the "2025 Outstanding New Product Award" at the ISBER awards in Canada, recognized for its technical innovation, industry influence, data support, and market demand [2] - In March 2025, Yuaneng Bio was selected for the National "High-Quality Medical Devices Going Abroad Selection Guide (2025)" [2]